Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Amgen and Bristol Myers Squibb represent different investment approaches in pharmaceuticals. Amgen demonstrates stronger revenue growth (~10% YoY) with higher profitability margins (21%) but trades at a premium valuation (P/E 26.4x). Bristol Myers Squibb offers significantly lower valuation (P/E 12.96x) and higher dividend yield (4.1%) with stronger free cash flow ($12.8B), though facing revenue headwinds and generic competition. For long-term dividend-focused investors, Bristol Myers Squibb is recommended despite near-term challenges.

10/20/2026, 5:45 PM • The Motley Fool

Europe Electronic Health Record (EHR) Market Size, Share, Trends, and Forecast, 2021 - 2031 | AI and Cloud Adoption Drive 9.9% CAGR, Creating a US$ 15.37 Billion Opportunity

Europe's EHR market is expected to grow from US$8.05 billion in 2024 to US$15.37 billion by 2031, driven by AI adoption, cloud-based solutions, and government digital health initiatives. Cloud-based systems lead the market, with acute EHR and clinical records as primary segments. Germany is the largest market contributor, supported by national digital strategy and mandatory e-prescriptions. Leading vendors are investing in product innovation, partnerships, and M&A to strengthen market presence.

10/20/2026, 12:00 PM • GlobeNewswire

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.

10/15/2026, 10:16 AM • The Motley Fool

Why Option Care Health Stock Skyrocketed on Tuesday

Option Care Health agreed to be acquired by McKesson and private equity firm Clayton, Dubilier & Rice for $32.05 per share, valuing the company at approximately $5.8 billion. The deal represents a 37% premium to Monday's closing price and is expected to close in the first half of 2027. CD&R will hold 51% of the company while McKesson retains 49%, with a framework allowing McKesson to acquire CD&R's stake in the future.

10/06/2026, 2:36 PM • The Motley Fool

Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation.

10/06/2026, 9:10 AM • The Motley Fool

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.

09/18/2026, 9:15 AM • The Motley Fool

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.

09/14/2026, 10:40 AM • The Motley Fool

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.

09/04/2026, 2:30 PM • The Motley Fool

McKesson Corporation: Ademi LLP Investigates Claims for Damages

McKesson disclosed a data breach on August 25, 2026, affecting 284 million records belonging to tens of millions of patients. Compromised information includes personal identities, healthcare identifiers, medical records, prescription data, and highly sensitive health information. Ademi LLP is investigating potential data privacy claims and advising affected individuals to monitor financial accounts and consider credit protection measures.

08/28/2026, 10:37 PM • GlobeNewswire

Worried About the Market? These Stocks Have a Track Record of Helping Investors Sleep at Night.

The article recommends three healthcare dividend growth stocks for investors seeking portfolio stability during market volatility: Johnson & Johnson (a Dividend King with 64 consecutive years of dividend increases), UnitedHealth Group (rebounding after recent challenges with a 2.26% yield), and McKesson (the largest U.S. pharmaceutical distributor with steady dividend growth). Healthcare is highlighted as a defensive sector due to non-discretionary spending patterns.

08/06/2026, 10:15 AM • The Motley Fool

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Eli Lilly and Teva Pharmaceutical represent two different pharmaceutical strategies: Eli Lilly dominates the high-growth GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, posting 44% revenue growth and trading at a 33x forward P/E. Teva operates in generics and biosimilars with lower valuations (16.4x forward P/E) but faces declining sales projections for 2026 and significant debt challenges. The article recommends Eli Lilly as the better buy despite premium valuation due to its continued GLP-1 growth momentum.

07/06/2026, 1:09 PM • The Motley Fool

$663.3 Bn Revenue Cycle Management Market Trends and Global Forecasts Report 2026-2035

The global revenue cycle management (RCM) market is projected to grow at a CAGR of 11.51% from $200.1 billion in 2026 to $663.3 billion by 2035, driven by widespread EHR adoption, shift to value-based care models, and increasing use of AI and automation. North America holds the largest market share due to its complex healthcare system and advanced technology infrastructure. Key players include 3M, Change Healthcare, Optum, and McKesson, though high implementation costs and regulatory complexity present challenges.

05/21/2026, 4:57 AM • GlobeNewswire

Global Healthcare Analytics Market is Predicted to Cross the USD 380 Billion Mark by 2034 | DelveInsight

The global healthcare analytics market is projected to grow from USD 56 billion in 2025 to USD 390 billion by 2034, with a CAGR of ~24%. Growth is driven by widespread EHR adoption, rising chronic disease prevalence, shift toward value-based care, AI/ML integration, and government digital health initiatives. North America leads with 44.36% market share, while Asia-Pacific emerges as a major growth engine.

05/06/2026, 1:00 PM • GlobeNewswire

Robotic Pharmacy Prescription Market Research and Global Forecast Report 2025-2032

The global robotic pharmacy prescription market is experiencing significant growth, expanding from USD 214.16 million in 2025 to USD 237.65 million in 2026, with a projected CAGR of 9.18% through 2032, reaching USD 396.21 million. The market is driven by automation adoption for medication safety and efficiency, workforce transformation toward clinical roles, and bundled solution procurement strategies across hospitals, clinics, and long-term care facilities.

04/09/2026, 4:57 AM • GlobeNewswire

Biopharmaceutical Third Party Logistics (Distribution Management, Packaging & Labeling, Transportation, Warehousing) Market Research and Global Forecast Report 2026-2032

The biopharmaceutical third-party logistics market is expected to grow from $140.03 billion in 2025 to $384.23 billion by 2032, with a CAGR of 15.51%. Growth is driven by rising product complexity, regulatory scrutiny, cold chain integrity demands, and technological advancements in digital tracking and specialized handling for biologics and gene therapies.

04/09/2026, 4:49 AM • GlobeNewswire